Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.88 HKD | -0.15% | +2.08% | +2.99% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Sales 2024 * | 437M 60.34M 471M | Sales 2025 * | 800M 110M 863M | Capitalization | 4.43B 612M 4.78B |
---|---|---|---|---|---|
Net income 2024 * | -251M -34.65M -271M | Net income 2025 * | -3M -414K -3.23M | EV / Sales 2024 * | 8.4 x |
Net cash position 2024 * | 762M 105M 822M | Net cash position 2025 * | 706M 97.44M 761M | EV / Sales 2025 * | 4.66 x |
P/E ratio 2024 * |
-17.8
x | P/E ratio 2025 * |
-85.2
x | Employees | 444 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.42% |
1 day | -0.15% | ||
1 week | +2.08% | ||
Current month | +1.47% | ||
1 month | -5.75% | ||
3 months | +34.90% | ||
6 months | +2.08% | ||
Current year | +2.99% |
Managers | Title | Age | Since |
---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.59% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 6.88 | -0.15% | 585 000 |
24-06-05 | 6.89 | +0.44% | 830,500 |
24-06-04 | 6.86 | +0.44% | 1,102,500 |
24-06-03 | 6.83 | +0.74% | 945,600 |
24-05-31 | 6.78 | +0.59% | 1,170,500 |
Delayed Quote Hong Kong S.E., June 06, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.99% | 612M | |
+42.69% | 749B | |
+38.38% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+11.21% | 216B | |
-2.58% | 214B | |
+2.64% | 167B | |
+6.72% | 165B |
- Stock Market
- Equities
- 1477 Stock